COUNCIL TO CONSIDER EXTENDING RELIEF BY REDUCING GST RATES FROM 12% TO 5%, TILL ON FOLLOWING DRUGS: ITOLIZUMAB, POSACONAZOLE, INFLIXIMAB, BAMLANIVIMAB & ETESEVIMAB, CASIRIVIMAB & IMDEVIMAB, 2-DEOXY-D-GLUCOSE, FAVIPIRAVIR - SOURCES - CNBCTV18Major beneficial - #GLENMARK #CIPLA #LUPIN 🔥👆
